Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% ...
Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex ...
A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...
The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...
Number 4: In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in the biosimilars landscape, coinciding with ongoing legal disputes ...
On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which ...
A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment ...
Number 5: A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford University School of Medicine, gave an overview of patient-reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback